-
Mashup Score: 2
1. For patients with localized endometrial cancer recurrence, adding cisplatin to radiation therapy did not appear to improve progression-free survival when compared to radiation therapy alone. 2. For patients with localized endometrial cancer recurrence, adding cisplatin to radiation therapy resulted in higher rates of acute toxicity, when compared to radiation therapy alone. Evidence Rating Level:
Source: www.physiciansweekly.comCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 2David Scott Miller (@dsmgyo) • Instagram photo - 29 day(s) ago
4 likes, 0 comments – dsmgyo on April 2, 2024: “Congratulations to @utswmed #gynecologic #oncology fellow, Dr. Blaine Holloway @b_holloway2, on being awarded “Fellow of the Year” at…”
Source: www.instagram.comCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 1David Scott Miller (@dsmgyo) • Instagram reel - 2 month(s) ago
11 likes, 1 comments – dsmgyo on February 22, 2024: “I will be moderating Scientific Plenary V: Late Breaking Abstract Session 2 – “The Turning Point …”
Source: www.instagram.comCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 1Publisher Retracts Three Abortion Studies - 3 month(s) ago
Two of the studies were cited by a federal judge in the case against the abortion pill
Source: www.medpagetoday.comCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 4Patient-Reported Quality of Life in Patients With Endometrial Cancer Treated With Lenvatinib Plus Pembrolizumab - 3 month(s) ago
Researchers have found that a combination therapy of lenvatinib and pembrolizumab can have a statistically significant effect on health-related quality of life scores for patients with endometrial cancer.
Source: www.hmpgloballearningnetwork.comCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 7Selinexor Maintenance Therapy Post-First-Line Chemotherapy in Recurrent or Advanced EC: An Oral Approach - 4 month(s) ago
The following is a summary of “Oral Selinexor as Maintenance Therapy After First-Line Chemotherapy for Advanced or Recurrent Endometrial Cancer,” published in the December 2023 issue of Oncology by Vergote, et al. For a ENGOT-EN5/GOG-3055/SIENDO phase III study, researchers sought to evaluate the efficacy of once-weekly oral selinexor in advanced or recurrent endometrial cancer (EC)
Source: www.physiciansweekly.comCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 4
expert roundtables by David Scott Miller, MD, FACOG, FACS; Alexander B. Olawaiye, MD, FRCOG, FACOG, FACS; Pamela T. Soliman, MD, MPH Long-term survival in patients with endometrial cancer has increased with our understanding of the disease and its subtypes. Understanding predictive factors for survival in patients with endometrial cancer can help clinicians match each patient with the best treatment option. What are the best predictors of survival in patients with endometrial cancer? “As a result of The
Source: expertperspectives.comCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 9State-of-the-Art Management of Advanced or Recurrent Endometrial Cancer - Expert Perspectives - 5 month(s) ago
Standard options to treat primary advanced or recurrent endometrial cancer after failure of platinum-based chemotherapy have been limited. The emergence of immunotherapy and targeted therapies in this space has been encouraging, and researchers are aiming to build on these initial successes.
Source: expertperspectives.comCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 4
Particularly strong PFS signal seen in patients that were mismatch repair proficient
Source: www.medpagetoday.comCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 7Radiation Therapy for Medically Inoperable Endometrial Cancer - Expert Perspectives - 6 month(s) ago
Some patients with endometrial cancer are deemed medically inoperable due to factors such as advanced age and comorbidities that increase perioperative risk. For such patients, definitive radiation therapy is an option that can result in favorable local control and improved survival outcomes.
Source: expertperspectives.comCategories: General Medicine News, Hem/OncsTweet
The results of @NRGonc @GOG #238: addition of #cisplatin to #radiationtherapy does not appear to improve progression-free survival for patients with localized recurrent #endometrialcancer. Now online in @JCO_ASCO. From @physicianswkly. #gyncsm https://t.co/I5I215tBFX